Soligenix Inc
SNGX1.340USD
-0.130-8.84%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
4.70MMarket Cap
LossP/E TTM
More Details of Soligenix Inc Company
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Soligenix Inc Info
Ticker SymbolSNGX
Company nameSoligenix Inc
IPO dateApr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
Number of employees14
Security typeOrdinary Share
Fiscal year-endApr 04
Address29 Emmons Drive
CityPRINCETON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08540
Phone16095388200
Websitehttps://www.soligenix.com/
Ticker SymbolSNGX
IPO dateApr 04, 1994
CEODr. Christopher J. (Chris) Schaber, Ph.D.
Company Executives of Soligenix Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+3992.61%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Mr. Jonathan L. Guarino, CPA
Mr. Jonathan L. Guarino, CPA
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
--
--
Dr. Oreola Donini, Ph.D.
Dr. Oreola Donini, Ph.D.
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher J. (Chris) Schaber, Ph.D.
Dr. Christopher J. (Chris) Schaber, Ph.D.
Chairman of the Board, Chief Executive Officer and President
Chairman of the Board, Chief Executive Officer and President
15.51K
+3992.61%
Dr. Jerome B. Zeldis, M.D., Ph.D.
Dr. Jerome B. Zeldis, M.D., Ph.D.
Independent Director
Independent Director
96.00
--
Dr. Richard C. Straube, M.D.
Dr. Richard C. Straube, M.D.
Senior Vice President and Chief Medical Officer
Senior Vice President and Chief Medical Officer
34.00
--
Dr. Robert Joseph Rubin, M.D.
Dr. Robert Joseph Rubin, M.D.
Independent Director
Independent Director
19.00
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.08%
Connective Capital Management, LLC
1.43%
The Vanguard Group, Inc.
0.38%
Geode Capital Management, L.L.C.
0.36%
UBS Financial Services, Inc.
0.23%
Other
92.53%
Shareholders
Shareholders
Proportion
Intracoastal Capital, L.L.C.
5.08%
Connective Capital Management, LLC
1.43%
The Vanguard Group, Inc.
0.38%
Geode Capital Management, L.L.C.
0.36%
UBS Financial Services, Inc.
0.23%
Other
92.53%
Shareholder Types
Shareholders
Proportion
Corporation
5.08%
Hedge Fund
1.63%
Investment Advisor
0.66%
Investment Advisor/Hedge Fund
0.36%
Individual Investor
0.19%
Other
92.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
42
221.30K
2.64%
-129.44K
2025Q2
50
150.04K
4.60%
-125.61K
2025Q1
50
149.55K
4.59%
-122.83K
2024Q4
62
34.48K
1.37%
-224.66K
2024Q3
62
66.84K
2.91%
-140.04K
2024Q2
61
101.18K
6.59%
-9.86K
2024Q1
57
15.87K
2.48%
-90.98K
2023Q4
55
24.60K
3.87%
-67.56K
2023Q3
57
57.20K
9.40%
-37.02K
2023Q2
61
91.32K
18.32%
+80.79K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Intracoastal Capital, L.L.C.
425.00K
5.08%
+425.00K
--
Sep 25, 2025
Connective Capital Management, LLC
119.48K
1.43%
+17.85K
+17.56%
Jun 30, 2025
The Vanguard Group, Inc.
2.19K
0.03%
--
--
Aug 31, 2025
Geode Capital Management, L.L.C.
29.86K
0.36%
+491.00
+1.67%
Jun 30, 2025
UBS Financial Services, Inc.
19.42K
0.23%
+8.95K
+85.53%
Jun 30, 2025
Schaber (Christopher J)
379.00
0%
--
--
Sep 25, 2025
Citadel Advisors LLC
15.16K
0.18%
+15.16K
--
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.59K
0.04%
--
--
Jun 30, 2025
Tower Research Capital LLC
1.39K
0.02%
+1.39K
--
Jun 30, 2025
Plante Moran Financial Advisors, LLC
300.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Date
Type
Ratio
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Apr 29, 2024
Merger
16→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
Feb 09, 2023
Merger
15→1
